Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
MBP-K007 | Human | PSMA-coupled magnetic beads | |||
PSA-H5264 | Human | Human PSMA / FOLH1 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
PSA-M5245 | Mouse | Mouse PSMA / FOLH1 Protein, His Tag (active enzyme) | ![]() |
![]() ![]() |
|
PSA-C5247 | Cynomolgus | Cynomolgus PSMA / FOLH1 Protein, His Tag (MALS verified) (active enzyme) | ![]() |
![]() ![]() |
![]() ![]() |
PSA-HF244 | Human | FITC-Labeled Human PSMA / FOLH1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
PSA-H82Qb | Human | Biotinylated Human PSMA / FOLH1 Protein, His,Avitag™ (active enzyme) | ![]() |
![]() ![]() |
![]() ![]() |
PSA-H52H3 | Human | Human PSMA / FOLH1 Protein, His Tag (MALS verified) (active enzyme) | ![]() |
![]() ![]() |
![]() ![]() |
FACS analysis of Human PSMA, Fc Tag binding to PSMA-CAR-293 cells transfected with anti-PSMA-scFv 2X105 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Human PSMA, Fc Tag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routinely tested).
Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
The purity of Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) was more than 85% and the molecular weight of this protein is around 185-220 kDa verified by SEC-MALS.
Immobilized Cynomolgus PSMA, His Tag (Cat. No. PSA-C5247) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Capromab pendetide | CYT-356; 111In CYT-356; lndium-CYT-356; Indium-111-CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | s:7:"Cytogen"; | 1996-10-28 | Prostatic Neoplasms | Details |
Gallium GA-68 PSMA-11 | Ga-68-PSMA-11; Ga-68-PSMA | Approved | Radiomedix | Gallium Ga 68 Psma-11 | United States | Prostatic Neoplasms | s:37:"University Of California, Los Angeles"; | 2020-12-01 | Prostatic Neoplasms | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AMG-160 | AMG-160 | Phase 1 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics | Neoplasms | Details | |
MOR-209/ES414 | APVO-414; MOR-209; ES-414 | Phase 1 Clinical | Emergent | Prostatic Neoplasms | Details |
Gallium-68 PSMA-617 | PSMA-617-[68Ga]; 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; 68Ga-DKFZ-PSMA -617 | Clinical | Deutsches Krebsforschungszentrum, University Of Heidelberg | Prostatic Neoplasms | Details |
P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
CC-1 | CC-1 | Phase 1 Clinical | The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz | Prostatic Neoplasms | Details |
CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
HPN-424 | HPN-424 | Phase 2 Clinical | Harpoon Therapeutics | Prostatic Neoplasms | Details |
PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | Shanghai Bioray Laboratory Inc | Prostatic Neoplasms | Details | |
INO-5401 | INO5401; INO-5401 | Phase 2 Clinical | Inovio | Glioblastoma; Carcinoma, Transitional Cell | Details |
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
ATL-101 (ATLAB) | J-591; MLN-591; huJ-591; muJ-591; 90Y-J591; MLN-591RL; 177Lu-J591; Lu-177-J591 | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
[131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466 | Phase 2 Clinical | Progenics Pharmaceuticals Inc | Prostatic Neoplasms | Details |
89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
Df-IA2BM-Zr-89 | IAB2M; 89Zr-Df-IAB2M; Df-IA2BM-Zr-89; 64Cu-NODAGA-PSMA-Mb | Phase 2 Clinical | Imaginab | Prostatic Neoplasms; Glioma | Details |
INO-5150 | INO-5150 | Phase 1 Clinical | Inovio | Prostatic Neoplasms | Details |
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details | |
177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6 | Phase 2 Clinical | Advanced Accelerator Applications | Prostatic Neoplasms | Details |
[18F]DCFPyL | Phase 3 Clinical | Johns Hopkins University | Carcinoma, Renal Cell; Prostatic Neoplasms | Details | |
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Clinical | Advanced Accelerator Applications | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.